Nivolumab and chemotherapy before surgery and radiation for salivary cancer
Part of Cancer clinical trials.
This Phase 2 study tests giving nivolumab plus docetaxel and cisplatin before surgery and radiation for certain resectable, high-grade salivary gland cancers. It aims to shrink or control the cancer early to improve outcomes after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have resectable high-grade salivary gland cancer of a specific type (with confirmed biopsy), including certain subtypes like adenoid cystic or salivary duct cancer
- The cancer has not been treated with chemotherapy (no prior chemo) before joining
- You have no prior immune checkpoint medicines such as anti-PD-1, anti-PD-L1, anti–PD-L2, or CTLA-4–type drugs
- You are well enough for treatment (ECOG 0–1) and expected to live at least 3 months
- Recent imaging shows at least one target spot (measurable or non-measurable lesion) to track response
- Blood tests and organ function are strong enough for treatment (specific blood counts, liver, and kidney levels)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving an immunotherapy drug (sintilimab) plus two chemotherapy medicines before surgery to shrink salivary gland cancer. The goal is to improve how well the cancer responds and is controlled, while still aiming for a cure through surgery.
This study tests giving radiation and chemotherapy together after surgery for aggressive salivary gland cancers of the head and neck. It aims to see how well this standard treatment works in real-world settings.
This trial studies toripalimab (an immune medicine) combined with chemotherapy given before surgery for salivary gland cancer. It aims to shrink the tumor and improve outcomes by using treatment early, before the operation.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This study tests a combination of a targeted cancer drug (antibody-drug conjugate) and focused radiation therapy for salivary gland cancers that have come back or spread after initial treatment. It may help patients whose cancer didn't respond to standard options.
This Phase 2 trial studies whether adding dutasteride to standard anti-androgen therapy can shrink or slow an advanced salivary gland cancer. It is for cancers that test “androgen receptor (AR) positive,” meaning they may respond to medicines that block male-hormone signals.
Hear when a new High-grade Salivary Gland Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.